Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor - PubMed (original) (raw)

Affiliations

PMID: 2262914

Comparative Study

Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor

H O Heuer et al. J Pharmacol Exp Ther. 1990 Dec.

Abstract

The hetrazepine WEB 2170 (international nonproprietary name: bepafant), a thieno-triazolodiazepine that is structurally related to the recently described platelet activating factor (PAF) antagonist WEB 2086, is a potent and selective PAF antagonist both in vitro and in vivo. WEB 2170 inhibited PAF-induced human platelet and neutrophil aggregation in vitro (IC50 values: 0.3 and 0.83 microM, respectively) but had little or no inhibitory action against aggregation induced by other agonists. The potency in vitro was comparable to that described recently for WEB 2086 (Casals-Stenzel, J., Muacevic, G. and Weber, K.H.: J. Pharmacol. Exp. Ther. 241: 974-981, 1987). When guinea pigs were given i.v. infusions of PAF at 30 ng x kg-1 x min-1, oral (0.005-0.5 mg/kg) as well as intravenous (0.005-0.05 mg/kg) treatment with WEB 2170 abrogated the intrathoracic accumulation of 111In-labeled platelets, the bronchoconstriction and the hypotension as well as the finally occurring death in a dose-dependent fashion. Oral (0.01-1 mg/kg) and intravenous (0.005-0.1 mg/kg) WEB 2170 shared with the beta 2 agonist fenoterol and the steroid dexamethasone the property of protecting elderly NMRI mice from the lethal effect of PAF. In anesthetized rats, intravenous (0.001-0.1 mg/kg) and oral (0.05-1 mg/kg) WEB 2170 inhibited PAF-induced hypotension in a dose-related manner. Coadministration of WEB 2170 inhibited PAF-induced increase of vascular permeability in rat skin very effectively. The half-time of duration of action in the rat was estimated to be about 5 to 6 h after oral administration and about 1.1 to 2.3 h after intravenous application. In conclusion, the hetrazepine WEB 2170 is a strong and selective PAF antagonist, which is in vitro more or less equipotent to WEB 2086. In contrast, in vivo oral WEB 2170 is--depending on the species and considered parameter--about 5 to 40 times more potent against exogenous PAF-induced alterations than the recently described hetrazepine WEB 2086. Particularly in mice and rats, oral WEB 2170 is by far superior to WEB 2086.

PubMed Disclaimer

Cited by

The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils.
Lupia E, Del Sorbo L, Bergerone S, Emanuelli G, Camussi G, Montrucchio G. Lupia E, et al. Immunology. 2003 Aug;109(4):557-63. doi: 10.1046/j.1365-2567.2003.01692.x. Immunology. 2003. PMID: 12871223 Free PMC article.
Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis.
Montrucchio G, Lupia E, Battaglia E, Passerini G, Bussolino F, Emanuelli G, Camussi G. Montrucchio G, et al. J Exp Med. 1994 Jul 1;180(1):377-82. doi: 10.1084/jem.180.1.377. J Exp Med. 1994. PMID: 7516414 Free PMC article.
Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model.
Silliman CC, Voelkel NF, Allard JD, Elzi DJ, Tuder RM, Johnson JL, Ambruso DR. Silliman CC, et al. J Clin Invest. 1998 Apr 1;101(7):1458-67. doi: 10.1172/JCI1841. J Clin Invest. 1998. PMID: 9525989 Free PMC article.
Influence of a platelet-activating factor antagonist on severe pancreatitis in two experimental models.
Leonhardt U, Fayyazzi A, Seidensticker F, Stöckmann F, Söling HD, Creutzfeldt W. Leonhardt U, et al. Int J Pancreatol. 1992 Oct;12(2):161-6. doi: 10.1007/BF02924640. Int J Pancreatol. 1992. PMID: 1460331
A PAF receptor antagonist inhibits acute airway inflammation and late-phase responses but not chronic airway inflammation and hyperresponsiveness in a primate model of asthma.
Gundel RH, Wegner CD, Heuer HO, Letts LG. Gundel RH, et al. Mediators Inflamm. 1992;1(6):379-84. doi: 10.1155/S0962935192000577. Mediators Inflamm. 1992. PMID: 18475488 Free PMC article.

Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor - PubMed (original) (raw)